CID 078
Alternative Names: CID-078Latest Information Update: 11 Sep 2024
At a glance
- Originator Circle Pharma
- Class Antineoplastics; Macrocyclic compounds; Peptides
- Mechanism of Action Cyclin A inhibitors; Cyclin B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 09 Sep 2024 Pharmacodynamics data from preclinical trial in Solid tumours released by Circle Pharma
- 14 Aug 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06577987)
- 01 Jul 2024 Circle Pharma files an IND application with the US FDA for Solid tumours